Major UK Trial Offers New Hope for Endometriosis Pain Management

A landmark £2.3 million study has begun preliminary work for a five-year clinical trial aiming to revolutionise how endometriosis is managed in the UK. Led by the University of Aberdeen and NHS Grampian, the research focuses on an endometriosis-specific pain management programme (e-PMP) that could provide long-term relief for patients who find little success with surgery or medication alone.

Endometriosis is often misunderstood as merely painful menstruation, but it is actually a systemic inflammatory condition where tissue similar to the womb lining grows elsewhere, such as on the bowel or lungs. This growth creates severe, raw sores and can lead to years of diagnostic delays. There is currently no cure, leaving patients to cope with debilitating pain that frequently disrupts their mental health, education, careers, and relationships.

Charlotte McCann, a 27-year-old from Huntly in Aberdeenshire, is one of the women hoping the trial will make a difference. Diagnosed with stage 4 endometriosis, McCann was forced to abandon her career in corporate finance because her pain became intolerable. She described waking up vomiting at night and struggling to stand or sit upright, eventually losing significant weight due to the severity of her symptoms and the side effects of strong opioid painkillers.

“Endometriosis has had a huge impact on my life, and I am delighted to hear that they are looking at new ways to help the millions of women who are suffering with this every single day,” McCann said. Despite undergoing surgery to remove tissue, her symptoms returned, highlighting the need for alternative treatment strategies.

The upcoming trial will recruit pre-menopausal women and assign them to either the new personalised programme or standard care alone. The e-PMP is a 12-week interdisciplinary approach that combines cognitive behavioural therapy-informed psychotherapy, specialist physiotherapy, and guidance on intimacy and communication, alongside medications to manage side effects.

Dr Lucky Saraswat, consultant gynaecologist and lead for the Aberdeen Endometriosis Centre, emphasised that endometriosis remains one of the most common yet under-researched causes of chronic pain. “Many women continue to suffer even after surgery or medication,” she noted. If the trial proves effective, the programme could become a vital option for women seeking to avoid repeated surgeries, hormonal therapies, or those planning pregnancies.

Prof Anthony Gordon, director of the National Institute for Health and Care Research’s health technology assessment programme, stated that high-quality research is essential to break the cycle of agonising symptoms. He added that the trial could “revolutionise care” by delivering support that addresses the complex, full-scale impact of the disease. Emma Cox, chief executive of Endometriosis UK, welcomed the study as a much-needed step toward improving management options for those living with chronic pelvic pain.